Life Sciences

  • February 04, 2026

    Stem-Cell Drug Developer PrimeGen Inks $1.5B SPAC Merger

    Regenerative medicine developer PrimeGen US said Wednesday it has agreed to go public through a merger with blank check company DT Cloud Star Acquisition Corp., in a deal that values the company at about $1.5 billion.

  • February 04, 2026

    Whoop Nabs Block On Chinese Co.'s Health-Tracker Products

    A Massachusetts federal judge has blocked a Chinese company from selling in the U.S. its health-tracking products that were alleged by health band maker Whoop Inc. to be infringing its trade dress.

  • February 04, 2026

    Drugmakers Say Hagens Berman Responsible For Costs

    Drugmakers including GSK and Sanofi have told a Pennsylvania federal court that plaintiffs firm Hagens Berman Sobol Shapiro LLP should bear the costs for the special master tasked with sorting out long-running disputes in a since-dropped product liability suit.

  • February 04, 2026

    Fertility Clinic Says Doctors Lured Staff To New Practice

    The owners of a Massachusetts fertility clinic say three doctors left to start their own practice and repeatedly violated a non-solicitation agreement to "raid" its staff, according to a complaint filed in state court.

  • February 04, 2026

    Ex-Hogan Lovells Regulatory Atty Moves To Honigman In DC

    An attorney specializing in guiding life sciences companies through the U.S. Food and Drug Administration's regulatory process has moved her practice to Honigman LLP's Washington, D.C., office after more than 11 years with Hogan Lovells.

  • February 04, 2026

    Drugmaker Claims Stake In La. Mail-Order Abortion Meds Row

    An abortion medication manufacturer asserted its right Wednesday to defend mifepristone, moving to intervene in a federal lawsuit over mail-order abortion medication brought by Louisiana alleging that regulators violated federal law by removing an in-person dispensing requirement for the drug.

  • February 04, 2026

    Express Scripts Makes 'Fundamental Changes' In FTC Deal

    Express Scripts on Wednesday agreed to what the Federal Trade Commission called a "landmark settlement" promising major changes to its drug formulary practices, allowing the company to duck out of a case accusing all three of the country's largest pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • February 03, 2026

    ImmunityBio Stockholder Targets Soon-Shiong In Chancery

    The Delaware Chancery Court on Tuesday heard arguments over whether biotech billionaire Patrick Soon-Shiong and ImmunityBio Inc.'s board breached their fiduciary duties by approving insider financing that allegedly allowed him to secure equity at deeply discounted prices as the company neared regulatory approval for its lead cancer drug.

  • February 03, 2026

    Squires And Stewart's Patent Office, By The Numbers

    The U.S. Patent and Trademark Office has seen sweeping changes under Director John Squires and Deputy Director Coke Morgan Stewart, ranging from pro-patent owner policies at the Patent Trial and Appeal Board to employment shake-ups that have prompted departures from the agency.

  • February 03, 2026

    Medtronic's Bundling Isn't Anticompetitive, Prof Tells Jury

    A University of Chicago economics professor testified Tuesday in a California federal trial over antitrust claims against Medtronic, saying its practice of bundling its advanced bipolar devices for sales with other products isn't anticompetitive but is actually a very common American practice used by the likes of McDonald's and Costco. 

  • February 03, 2026

    Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK

    Masimo Corp. and its investors have received initial approval of a $33.8 million deal to settle claims that the medical and audio device company based its sales and revenue projections on unrealistic expectations for demand.

  • February 03, 2026

    Trump Admin Sued Over 'Pay-To-Play' Gold Card Program

    Immigrants and an academic professionals union filed suit Tuesday to block President Donald Trump's "gold card" visa program, telling a D.C. federal court that the "pay-to-play" program unlawfully takes visas away from professionals the existing employment-based visa system prioritizes.

  • February 03, 2026

    Medical Transport Co. Misclassified Drivers, Suit Says

    A company that transports radioactive medical materials misclassified drivers as independent contractors, leading to minimum wage and overtime violations, according to a proposed class and collective action filed in Florida federal court.

  • February 03, 2026

    Novartis, Sandoz Face New Generic-Drug Price-Fixing Suit

    Adding to sprawling antitrust litigation against pharmaceutical giants, 42 states and territories sued Novartis AG, Sandoz AG and other drug companies in Connecticut federal court Monday, alleging that the companies colluded for years to fix prices and control markets for generic drugs.

  • February 03, 2026

    Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says

    A clinical trial services company is suing Definium Therapeutics Inc. in Delaware federal court, alleging that it stole trade secrets during Phase 2 trials of LSD treatments for psychiatric disorders, then passed those secrets on to a rival services company for Phase 3 trials.

  • February 03, 2026

    Amway Looks To Sidestep Gut Drink Trademark Fight In NC

    Multi-level marketing giant Amway is seeking an early exit from a trademark infringement suit brought by a supplement maker in North Carolina, saying it has no ties to the Tar Heel state sufficient to be dragged into court there.

  • February 03, 2026

    Alston & Bird Adds Healthcare Regulatory Pro From Goodwin

    Alston & Bird LLP has added a healthcare regulatory attorney previously with Goodwin Procter LLP as a partner in Chicago, the firm announced Tuesday.

  • February 02, 2026

    Wheeling & Appealing: The Latest Must-Know Appellate Action

    What happened to a GOP donor's $250,000 Swiss watch? Can cigarette warnings show jarring medical images? Will a circuit split of "far-reaching importance" for arbitration get even wider? That's a taste of the oral argument menu we'll help you digest in this preview of February's top appellate action.

  • February 02, 2026

    'Terumo Knew' Of Dangerous Emissions, Jury Told

    A pollution expert witness told a Colorado jury Monday in the latest trial over Terumo's alleged emissions of toxic ethylene oxide that the medical sterilizer was fully aware of the community emissions and their danger.

  • February 02, 2026

    'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit

    Moderna Inc. will have to face most of a rival mRNA vaccine developer's $5 billion patent suit over the company's COVID-19 vaccines at a trial in Delaware, a federal judge ruled on Monday, invoking "Star Trek" in a summary judgment order that left issues like patent invalidity up to the jury.

  • February 02, 2026

    Monthly Merger Review Snapshot

    U.S. enforcers reached three new merger settlements, while the Federal Trade Commission successfully blocked a $945 million heart valve deal and lodged an appeal for its case targeting Meta's past acquisitions.

  • February 02, 2026

    PTAB Sinks Samsung Challenge To Ouraring Patent

    The Patent Trial and Appeal Board has shot down Samsung Electronics Co. Ltd.'s challenge to an Ouraring Inc. smart ring patent amid an ongoing legal dispute that has spanned the board, federal district court and the U.S. International Trade Commission.

  • February 02, 2026

    1st Circ. Judge Wary Of Boston Bid To Revive PBM Opioid Suit

    The city of Boston faced pushback from a First Circuit judge on Monday as it argued it didn't miss its window to sue pharmacy benefit managers for their alleged role in the opioid epidemic.

  • February 02, 2026

    DLA Piper Adds Ex-Cooley Atty To Lead N. Calif. Practice

    DLA Piper announced Monday that it has added the former global chair of Cooley LLP's digital health group to lead its Northern California corporate and securities practice and bolster its capacity to advise life sciences and technology companies on transactions and other matters.

  • February 02, 2026

    Mintz Adds Winston & Strawn ITC Practice Co-Leader In DC

    Mintz Levin Cohn Ferris Glovsky and Popeo PC has grown its Washington, D.C., office by bringing a Winston & Strawn LLP equity partner as its International Trade Commission practice co-chair, strengthening the firm's intellectual property services with a patent litigator with two decades of experience.

Expert Analysis

  • FDA Biosimilar Guidance Should Ease Biologics Development

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, indicating that the agency may no longer routinely require comparative efficacy studies when other evidence provides sufficient assurance of biosimilarity, underscores the FDA's trust in analytical technology as a driver of biologics access, say attorneys at Hogan Lovells.

  • Litigation Funding Could Create Ethics Issues For Attorneys

    Author Photo

    A litigation investor’s recent complaint claiming a New York mass torts lawyer effectively ran a Ponzi scheme illustrates how litigation funding arrangements can subject attorneys to legal ethics dilemmas and potential liability, so engagement letters must have very clear terms, says Matthew Feinberg at Goldberg Segalla.

  • E-Discovery Quarterly: Recent Rulings On Dynamic Databases

    Author Photo

    Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.

  • How Litigating Antitrust Fix Helped GTCR Prevail In Court

    Author Photo

    An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.